EWTX250117P40000
- 0.00
- 0.000.00%
Edgewise Therapeutics Newsroom
Edgewise Rated as a New Hold at Stifel on a Balanced Risk-reward Setup
Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall
Edgewise Therapeutics: Semigran, Current CDO, Will Depart and Serve as Clinical Adviser to Ensure Smooth Transition >EWTX
Edgewise Therapeutics: Behrad Derakhshan, Ph.D. Promoted to Oper Chief >EWTX
Express News | Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
Stifel Maintains Edgewise Therapeutics(EWTX.US) With Hold Rating, Maintains Target Price $30
Stifel Initiates Edgewise Therapeutics(EWTX.US) With Hold Rating, Announces Target Price $30
Cautious Hold Rating for Edgewise Therapeutics Amid Uncertain Differentiation and Efficacy
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Edgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne
Express News | Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Edgewise Therapeutics Insider Sold Shares Worth $2,737,470, According to a Recent SEC Filing
Edgewise Therapeutics Is Maintained at Outperform by Evercore ISI Group
Edgewise Therapeutics Analyst Ratings
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50